AACR 2024 | Genomic predictors of adverse events in glioblastoma

Patrick Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a recent paper on clinical and genomic predictors of adverse events in newly diagnosed glioblastoma. Analysis of genomic sequencing data from patients with glioblastomas highlighted no major genomic predictors for adverse events. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.